Skip to main content

Table 1 Performance comparison across sample cohorts

From: The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes

Performance of genetic alterations (Variants and Fusions)
    Cancer prevalence used in calculation
    PPV NPV
Sample cohort Sensitivity Specificity 24 % 40 % 24 % 40 %
All VERA FNA (n = 88) 43 % (28–59) 84 % (70–93) 46 % (29–65) 64 % (46–79) 82 % (78–86) 69 % (62–75)
AUS/FLUS & FN/SFN only VERA FNA (n = 22) 33 % (1–91) 84 % (60–97) 40 % (9–82) 58 % (17–90) 80 % (64–90) 65 % (45–81)
Tissue (n = 63) 59 % (41–76) 74 % (55–88) 42 % (27–58) 61 % (44–75) 85 % (78–90) 73 % (63–81)
Combined VERA FNA and tissue (n = 151) 50 % (38–62) 80 % (69–88) 44 % (32–57) 63 % (50–73) 84 % (80–87) 71 % (65–76)